TD Cowen Maintains Buy Rating on Edwards Lifesciences

TD Cowen has maintained its Buy rating on Edwards Lifesciences. The analyst team made this decision considering the company's financial performance and growth potential. Edwards Lifesciences' strong balance sheet, innovative product portfolio, and market position support TD Cowen's positive outlook. For investors, this recommendation reflects the company's long-term growth expectations. This is not investment advice.

📊 EW — Piyasa Yorumu

■ neutral · 60%

While the news presents a positive analyst outlook for Edwards Lifesciences, technical indicators do not point to a clear direction. The RSI is neutral at 49, the MACD is below its signal line, and the price is below the 20-day moving average. Despite a 2.6% gain in the last close, a sideways trend is expected in the short term. Investors should watch the 50-day moving average at $81.84 as support and the 20-day moving average at $83.24 as resistance.

RSI 14

49.0

MACD

0.07

24h Δ

2.59%

Canlı Grafikler